JP2011026326A5 - - Google Patents

Download PDF

Info

Publication number
JP2011026326A5
JP2011026326A5 JP2010200674A JP2010200674A JP2011026326A5 JP 2011026326 A5 JP2011026326 A5 JP 2011026326A5 JP 2010200674 A JP2010200674 A JP 2010200674A JP 2010200674 A JP2010200674 A JP 2010200674A JP 2011026326 A5 JP2011026326 A5 JP 2011026326A5
Authority
JP
Japan
Prior art keywords
group
alkyl
hydrogen
alkylcarbonyl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010200674A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011026326A (ja
Filing date
Publication date
Priority claimed from US10/079,324 external-priority patent/US20030158188A1/en
Priority claimed from US10/364,210 external-priority patent/US7074805B2/en
Application filed filed Critical
Publication of JP2011026326A publication Critical patent/JP2011026326A/ja
Publication of JP2011026326A5 publication Critical patent/JP2011026326A5/ja
Pending legal-status Critical Current

Links

JP2010200674A 2002-02-20 2010-09-08 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物 Pending JP2011026326A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/079,324 US20030158188A1 (en) 2002-02-20 2002-02-20 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US10/364,210 US7074805B2 (en) 2002-02-20 2003-02-11 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003569203A Division JP4614662B2 (ja) 2002-02-20 2003-02-11 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物

Publications (2)

Publication Number Publication Date
JP2011026326A JP2011026326A (ja) 2011-02-10
JP2011026326A5 true JP2011026326A5 (OSRAM) 2011-11-24

Family

ID=27759931

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003569203A Expired - Fee Related JP4614662B2 (ja) 2002-02-20 2003-02-11 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物
JP2010200674A Pending JP2011026326A (ja) 2002-02-20 2010-09-08 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003569203A Expired - Fee Related JP4614662B2 (ja) 2002-02-20 2003-02-11 バニロイド受容体サブタイプ1(vr1)受容体を阻害する縮合アザ二環式化合物

Country Status (8)

Country Link
EP (1) EP1478363B1 (OSRAM)
JP (2) JP4614662B2 (OSRAM)
AT (1) ATE420644T1 (OSRAM)
CA (1) CA2476936A1 (OSRAM)
DE (1) DE60325834D1 (OSRAM)
ES (1) ES2319886T3 (OSRAM)
MX (1) MXPA04008073A (OSRAM)
WO (1) WO2003070247A1 (OSRAM)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60325025D1 (de) * 2002-02-15 2009-01-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1478363B1 (en) * 2002-02-20 2009-01-14 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
AU2003251828A1 (en) * 2002-07-12 2004-02-02 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US7375126B2 (en) 2003-06-12 2008-05-20 Abbott Laboratories Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
PL1658269T3 (pl) * 2003-06-12 2009-08-31 Abbvie Inc Związki skondensowane, które hamują receptor waniloidowy podtypu 1 (VR1)
CA2743534A1 (en) * 2003-08-05 2005-02-24 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
GB0319150D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0322016D0 (en) * 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
JP4935073B2 (ja) 2003-10-14 2012-05-23 味の素株式会社 エーテル誘導体
JP2007509846A (ja) * 2003-10-15 2007-04-19 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−ナフタレンおよび尿素誘導体
JP2007523888A (ja) * 2003-11-08 2007-08-23 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−キノリニル尿素誘導体
BRPI0513286A (pt) * 2004-07-15 2008-05-06 Japan Tobacco Inc compostos de benzamida condensada e inibidores de atividade de receptor vanilóide subtipo (vr1), suas composições farmacêuticas, pacote comercial, fármaco e respectivos usos
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
CN101426498A (zh) * 2006-04-18 2009-05-06 艾博特公司 香草素受体亚型1(vr1)的拮抗剂及其用途
TW200824687A (en) 2006-08-25 2008-06-16 Abbott Lab Compounds that inhibit TRPV1 and uses thereof
EP2134678A2 (en) 2006-12-20 2009-12-23 Abbott Laboratories N-(5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain
ES2576643T3 (es) 2007-03-09 2016-07-08 Second Genome, Inc. Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
DE102007018149A1 (de) 2007-04-16 2008-10-23 Grünenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
KR20100016593A (ko) * 2007-04-16 2010-02-12 그뤼넨탈 게엠베하 신규한 바닐로이드 수용체 리간드 및 약제의 제조를 위한 이의 용도
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
CN102036969A (zh) 2008-03-20 2011-04-27 雅培制药有限公司 制造作为trpv1拮抗剂的中枢神经系统药剂的方法
KR101252334B1 (ko) 2008-04-18 2013-04-08 주식회사 대웅제약 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도
KR101621444B1 (ko) 2008-07-02 2016-05-19 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염, 및 이를 포함하는 약학 조성물
CN105254557A (zh) 2009-05-29 2016-01-20 拉夸里亚创药株式会社 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
CN105829282B (zh) * 2013-12-19 2018-08-28 朗盛德国有限责任公司 用于生产邻苯二甲酰亚胺的方法
MX2017014344A (es) * 2015-05-11 2018-04-11 Abide Therapeutics Inc Metodos para el tratamiento de la inflacion o el dolor neuropatico.
CN107033087B (zh) * 2016-02-04 2020-09-04 西华大学 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
CN105906564B (zh) * 2016-05-05 2018-11-30 海南省药物研究所 化合物、制备方法及其用途
JOP20190108B1 (ar) 2016-11-16 2023-09-17 H Lundbeck As تركيبات صيدلانية
HUE064559T2 (hu) 2016-11-16 2024-03-28 H Lundbeck As MAGL inhibitor kristályos formája
US10696638B2 (en) * 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043694A (en) * 1960-05-23 1962-07-10 Eastman Kodak Co Novel class of 3-indazolinone developing agent
FR1344579A (fr) * 1961-11-23 1963-11-29 Sandoz Sa Nouveaux dérivés de l'indole et leur préparation
JPS5587771A (en) * 1978-12-27 1980-07-02 Teikoku Hormone Mfg Co Ltd 1-phenylisoquinoline derivative
DE3430310A1 (de) * 1984-08-15 1986-02-27 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue dopamin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS62116559A (ja) * 1985-11-18 1987-05-28 Sagami Chem Res Center 4−アシルメチリデン−4,5,6,7−テトラヒドロインド−ル誘導体及びその製造方法
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1991004027A1 (en) * 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
EP0518961A1 (fr) * 1990-03-07 1992-12-23 Aventis Pharma S.A. Derives de glycinamide, leur preparation et les medicaments les contenant
GB9307833D0 (en) * 1993-04-15 1993-06-02 Glaxo Inc Modulators of cholecystokinin and gastrin
JPH1087629A (ja) * 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
HK1042472B (zh) * 1999-02-22 2005-12-09 Medifron Dbt Co., Ltd. 作爲有效的香草类受体激动剂和镇痛药的含有树脂毒素药效基团的香草类类似物,其组合物以及应用
JP2001122895A (ja) * 1999-10-20 2001-05-08 Hamari Chemicals Ltd 新規なオピオイドペプチド誘導体
NZ521192A (en) * 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
WO2001098269A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
EP1301484A2 (en) * 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin receptor ligands
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
EP1414788A1 (en) * 2001-07-31 2004-05-06 Bayer HealthCare AG Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
MY138086A (en) * 2001-09-13 2009-04-30 Smithkline Beecham Plc Novel urea derivative as vanilloid receptor-1 antagonist
JP2004339061A (ja) * 2001-09-28 2004-12-02 Takeda Chem Ind Ltd ベンゼン誘導体、その製造法および用途
CA2468544A1 (en) * 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
GB0130550D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
JP2003192659A (ja) * 2001-12-26 2003-07-09 Bayer Ag フェニル尿素誘導体
JP2003192587A (ja) * 2001-12-26 2003-07-09 Bayer Ag 尿素誘導体
EP1478363B1 (en) * 2002-02-20 2009-01-14 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Similar Documents

Publication Publication Date Title
JP2011026326A5 (OSRAM)
IL192150A (en) Use of 2-amino-2- [4- (3-benzyloxyphenylthio) -2-chlorophyll} ethyl-1,3-propanadiol, or its acceptable medical salt or hydrate, for the preparation or treatment of inflammatory bowel disease
IL221573A (en) Imidazoquinolines and their use in the preparation of drugs for the treatment of proliferative and inflammatory and obstructive pulmonary diseases
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
IL181049A0 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
JP2007077157A5 (OSRAM)
IL193230A (en) Use of benzoxoborol derivatives in the preparation of drugs for the treatment of inflammatory diseases
JP2011057678A5 (OSRAM)
JP2011526924A5 (OSRAM)
EP3042910A3 (en) 2'-spiro-nucleosides for use in the therapy of hepatitis c
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
IL206039A0 (en) Pharmaceutically acceptable salts of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate and their use in therapy
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
JP2009531376A5 (OSRAM)
PL1817282T3 (pl) Pochodne kwasu fenoksyoctowego użyteczne do leczenia chorób układu oddechowego
JP2010536849A5 (OSRAM)
ATE448219T1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
JP2006528617A5 (OSRAM)
PL1937633T3 (pl) Pochodne kwasu bifenyloksyoctowego do leczenia choroby układu oddechowego
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
PL2422786T3 (pl) Nowe kombinacje środków leczniczych do leczenia chorób dróg oddechowych
IL217300A0 (en) Pyrazole derivatives' prepartion thereof, and therapeutic use thereof
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
JP2008502694A5 (OSRAM)
ZA200804609B (en) Interferon-alpha and C-phycocyanin for the treatment of autoimmune diseases, allergic disease sand cancer